Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Evidence-Based, Non-Conventional Multiple Myeloma Therapies: What Patients Should Know
Evidence-Based, Non-Conventional Multiple Myeloma Therapies: What Patients Should Know
Evidence-Based, Non-Conventional Multiple Myeloma Therapies: What Patients Should Know. What if a multiple myeloma therapy has scientific evidence behind it—but isn’t FDA-approved to treat myeloma?
That is the question behind this article.
Multiple myeloma patients are often told about conventional treatments such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, steroids, stem-cell transplantation, CAR-T therapy, and bispecific antibodies.
These therapies have undergone the regulatory process required for FDA approval for particular indications.
But they are not the only therapies being studied.
Researchers around the world are investigating vitamins, dietary compounds, medicinal mushrooms, microbiome interventions, plant-derived compounds, intravenous nutrients and other approaches that may have anti-myeloma activity.
- Some have only laboratory evidence.
- Some have been studied in animals.
- Some have been tested in people with multiple myeloma.
- A few have even been evaluated in randomized clinical trials.
Most, however, are not FDA-approved treatments for multiple myeloma.
That does not automatically mean they work. But it also does not mean there is no scientific evidence worth investigating.
This article examines that middle ground.
I am a long-term survivor of multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since I reached MM-free status in early 1999. I have learned that the best way to manage myeloma is to combine the best of conventional and evidence-based non-conventional therapies.
Chances are your oncologist won’t talk to you about evidence-based non-conventional therapies but I believe that MM patients and survivors need to know the basics of complementary therapies linked below as well as repurposed drugs.
- intravenous vitamin C therapy,
- prehabilitation and
- enhancing your gut microbiome
- healing your immune system after chemotherapy and radiation
Let me be clear. Conventional MM oncology and FDA-approved MM therapies are central to managing MM. I’m simply saying that I believe that MM patients live better, longer lives by learning about evidence-based, non-conventional MM therapies.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about MM.
Good luck,
David Emerson
Concepts Central to Managing Your Cancer
- Integrative Oncology: Combining Conventional and Natural Cancer Therapies
- Complementary Cancer Therapies: Evidence-based
- Managing Cancer Treatment Side Effects: An Evidence-Based Guide to Prevention, Relief, and Recovery
- Beware of Financial Toxicity in Multiple Myeloma
- Smoldering Multiple Myeloma Progression: How Fast Does SMM Become Active Myeloma?
What Does “Non-Conventional” Mean?
For purposes of this PeopleBeatingCancer article, non-conventional multiple myeloma therapies are therapies that are not FDA-approved as treatments for multiple myeloma.
This is an important distinction.
“Non-conventional” does not necessarily mean:
- ineffective
- unscientific
- unsafe
- alternative medicine
- a replacement for conventional treatment
It simply means that the therapy does not have FDA approval as a multiple myeloma treatment.
This category includes dietary supplements, natural compounds, and other investigational approaches.
The FDA states that vitamins, minerals, herbs, and other dietary supplements are not FDA-approved to treat or prevent disease. The agency also explains that dietary supplements are regulated differently from drugs and are not subjected to the same premarket approval process for safety and effectiveness.
That regulatory distinction is important when evaluating the research.
FDA Approval Is Not the Same Thing as Scientific Evidence
There is an important misconception on both sides of the conventional-versus-alternative debate.
Some people assume:
“If the FDA hasn’t approved it, there is no evidence.”
That isn’t necessarily true.
Conversely, others assume:
“If a study shows that a natural compound kills myeloma cells, the treatment works.”
That isn’t true either.
There are several levels of evidence between those two extremes.
Level 1: Laboratory evidence
Researchers expose myeloma cells to a compound and observe what happens.
This can identify potentially important mechanisms.
But a laboratory result does not demonstrate that the treatment works in humans.
Level 2: Animal evidence
Researchers test the therapy in an animal model.
This provides additional information but still does not establish clinical effectiveness in people.
Level 3: Observational human evidence
Researchers observe what happens in people who use a therapy.
This can generate useful hypotheses but cannot reliably establish cause and effect.
Level 4: Early clinical trials
Researchers give the therapy to human participants to study safety, dosage, biological effects and preliminary efficacy.
Level 5: Randomized clinical trials
Participants are randomly assigned to different treatment groups.
This is considerably stronger evidence.
Level 6: Repeated, well-designed clinical trials
When independent studies repeatedly demonstrate benefit, confidence in the treatment increases.
Why Study Non-Conventional Multiple Myeloma Therapies?
Multiple myeloma remains an incurable malignancy for most patients, even though treatment has improved dramatically.
Patients with relapsed or refractory disease may eventually have fewer effective conventional options.
That creates a legitimate scientific reason to investigate additional therapies.
Natural compounds are particularly interesting because many contain biologically active molecules that can influence:
- inflammation
- apoptosis
- oxidative stress
- angiogenesis
- immune signaling
- cellular proliferation
- metabolism
- the tumor microenvironment
- drug resistance
Researchers have identified numerous plant-derived and natural compounds with potential anti-myeloma activity.
A review of traditional Chinese medicinal compounds, for example, identified curcumin, resveratrol, berberine, baicalein, and several other compounds with laboratory evidence of activity against multiple myeloma biology. The authors emphasized that larger, well-designed clinical trials are still needed.
That is exactly the distinction this article is intended to make.
Interesting biology is not the same as proven treatment.
1. Curcumin
Curcumin is probably one of the most interesting non-conventional compounds currently discussed in relation to multiple myeloma.
PeopleBeatingCancer has already published several articles about curcumin, including:
Curcumin vs. Multiple Myeloma: The Scientific Evidence Continues to Pile Up
and
Multiple Myeloma Therapy – Curcumin
Curcumin has been investigated for effects on several biological pathways relevant to myeloma, including NF-κB, inflammatory signaling, angiogenesis and cellular survival.
More importantly, curcumin has moved beyond purely laboratory research.
A randomized clinical trial
A small randomized clinical trial involving 33 patients evaluated curcumin as an adjunct to melphalan and prednisone.
The investigators reported higher overall remission in the curcumin group than in the control group—75% versus 33.3%. The study also reported changes in several biological markers.
That is an interesting finding.
But it is not definitive proof that curcumin is an effective multiple myeloma treatment.
The study was small, single-center, and relatively short.
PeopleBeatingCancer Evidence Rating
🟡 Promising — preliminary human evidence
Curcumin is one of the non-conventional myeloma therapies that deserves substantially more clinical research.
2. Medicinal Mushrooms
Medicinal mushrooms represent another intriguing category.
PeopleBeatingCancer has previously written:
Mushrooms: Non-Toxic Complementary Multiple Myeloma Therapy
One of the more interesting human studies investigated an extract based primarily on Agaricus blazei Murrill in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.
Forty patients were randomized to receive either the mushroom preparation or placebo.
Researchers reported differences in several immune parameters, including T-regulatory cells, plasmacytoid dendritic cells and cytokines.
This is important because it represents human clinical research, rather than merely a laboratory experiment.
However, the study was small and focused primarily on immunologic outcomes.
It did not establish that medicinal mushrooms improve multiple myeloma survival.
PeopleBeatingCancer Evidence Rating
🟡 Promising — early human evidence
Medicinal mushrooms deserve additional research, but they should not be represented as an established myeloma treatment.
3. Resveratrol
Resveratrol is a naturally occurring polyphenol found in foods such as grapes and berries.
PeopleBeatingCancer has previously examined:
Multiple Myeloma Therapy – Resveratrol
Laboratory research has identified potentially important effects on cancer-cell signaling, apoptosis, and other pathways involved in tumor biology.
But resveratrol illustrates why evidence needs to be examined carefully.
A review of resveratrol as a cancer therapy concluded that poor pharmacokinetics and low potency are major obstacles to translating laboratory findings into clinical treatment. The review also discusses concerns about nephrotoxicity in multiple myeloma patients.
In other words:
A compound can have interesting anti-cancer activity in the laboratory and still fail as a human therapy.
PeopleBeatingCancer Evidence Rating
🟠 Experimental — primarily preclinical evidence
Resveratrol is scientifically interesting, but clinical evidence is currently inadequate to consider it an established myeloma treatment.
4. The Gut Microbiome and Probiotics
This may become one of the most important areas of non-conventional myeloma research.
PeopleBeatingCancer has previously published:
The question is larger than whether a particular probiotic capsule helps.
Researchers are investigating whether the gut microbiome itself influences multiple myeloma biology and treatment response. As well as treatment-induced side effects.
- For example, researchers have found associations between intestinal microbiota composition and minimal residual disease status in multiple myeloma.
- Another study found associations between short-chain fatty acids produced by gut bacteria and treatment response, with butyrate and propionate showing potentially important biological effects.
- And very recent research has reported an association between dietary fiber intake, gut-microbiome changes, and treatment response in multiple myeloma patients.
These findings are fascinating.
But there is a major difference between:
“The microbiome appears to influence myeloma biology.”
and:
“Take this probiotic and your myeloma will improve.”
The first statement has growing scientific support.
The second has not been established.
PeopleBeatingCancer Evidence Rating
🟡 Promising — rapidly emerging human evidence
The microbiome may eventually become an important component of personalized myeloma treatment.
5. Dietary Fiber and the Myeloma Microbiome
The microbiome research has produced an especially interesting new question:
Can diet influence myeloma treatment response through the gut microbiome?
A 2026 study published in Blood Advances reported that higher dietary fiber intake was associated with increased treatment response in multiple myeloma patients along with changes in gut microbiome composition.
This does not prove that increasing fiber will treat multiple myeloma.
But it provides a strong rationale for further investigation.
It also provides an important bridge to PeopleBeatingCancer’s existing article:
The emerging research suggests that diet may matter not simply because of calories, vitamins or antioxidants, but because food changes the microbial environment in which the immune system and cancer cells interact.
PeopleBeatingCancer Evidence Rating
🟡 Promising — emerging human evidence
6. Vitamin D
Vitamin D occupies a somewhat different position.
Vitamin D is an essential nutrient and has well-established importance for bone and calcium metabolism.
PeopleBeatingCancer has previously discussed vitamin D in the context of myeloma and bone health.
But there is a difference between:
correcting vitamin D deficiency
and
using high-dose vitamin D as an anti-myeloma therapy.
The first is standard nutritional and medical care when deficiency exists.
The second remains investigational.
This distinction is particularly important for people with multiple myeloma because kidney function, calcium levels and bone disease can all affect decisions about vitamin D supplementation.
PeopleBeatingCancer Evidence Rating
🟢 Strong rationale for correcting deficiency
🟠 Insufficient evidence as a direct anti-myeloma treatment
7. Omega-3 Fatty Acids
Omega-3 fatty acids are another nutritional intervention worth investigating.
Sources include:
- fatty fish
- fish oil
- flaxseed
- chia seeds
- walnuts
- algae-derived products
Omega-3 fatty acids have important effects on inflammation and cellular signaling.
However, evidence that omega-3 supplementation directly treats multiple myeloma remains limited.
That makes omega-3s a good example of why the phrase “evidence-based” needs context.
There may be good evidence for omega-3s in general nutrition and cardiovascular health without there being good evidence that omega-3 supplements kill myeloma cells.
PeopleBeatingCancer Evidence Rating
🟢 Nutritional value
🟠 Insufficient evidence as a direct anti-myeloma treatment
8. Intravenous Vitamin C
High-dose intravenous vitamin C is frequently discussed as a non-conventional cancer therapy.
The rationale is biologically interesting: pharmacologic concentrations of vitamin C delivered intravenously can produce concentrations that cannot be achieved through ordinary oral supplementation.
However, that does not establish IV vitamin C as an effective treatment for multiple myeloma.
Research remains investigational, and questions remain regarding:
- appropriate dose
- patient selection
- treatment combinations
- efficacy
- kidney function
- safety
For that reason, IV vitamin C belongs in the experimental rather than established-treatment category.
PeopleBeatingCancer Evidence Rating
🟠 Experimental
Interesting enough to study.
Not established enough to substitute for conventional myeloma treatment.
9. Other Natural Compounds Under Investigation
Curcumin and resveratrol are only two examples.
Researchers have investigated numerous compounds for potential anti-myeloma effects, including:
- Berberine
- EGCG from green tea
- Quercetin
- Baicalein
- Ginseng compounds
- Flavonoids
- Other polyphenols
- Traditional Chinese medicinal compounds
A review of natural compounds investigated in multiple myeloma identified numerous mechanisms involving proliferation, apoptosis, autophagy, cell-cycle regulation, osteogenic differentiation, and drug resistance.
But most of these compounds remain at the laboratory or early-development stage.
This is an area where PeopleBeatingCancer should watch the science rather than overstate it.
10. Antineoplastons
Antineoplastons are perhaps the most controversial therapy in the PeopleBeatingCancer non-conventional treatment library.
PeopleBeatingCancer has published extensively about:
Antineoplaston Therapy for Multiple Myeloma
This topic is also different from nutritional supplements.
Antineoplastons have been proposed as anti-cancer agents, but convincing randomized clinical evidence demonstrating improved multiple myeloma survival has not been established.
This creates an important distinction between:
personal experience
and
clinical evidence.
A patient’s experience can be real and important without establishing that a therapy is effective for the general population.
PeopleBeatingCancer Evidence Rating
🔴 Insufficient clinical evidence
Antineoplastons remain experimental.
Evidence-Based Does Not Mean FDA-Approved
This is perhaps the most important idea in this entire article.
FDA approval and scientific evidence are related, but they are not interchangeable concepts.
A therapy can have:
- biological evidence but no human evidence
- animal evidence but no clinical evidence
- early human evidence but no definitive trials
- randomized clinical evidence but no FDA approval
- FDA approval for one disease but not another
The last category is particularly important.
An FDA-approved drug can sometimes be used off-label for a disease or indication that the FDA has not specifically approved. FDA explains that off-label use means using an approved drug for an unapproved disease, condition, dose, route or other use.
That is different from an entirely unapproved compound or dietary supplement.
The PeopleBeatingCancer Evidence Rating System
🟢 Established supportive evidence
There is reasonable human evidence for the particular purpose being discussed.
🟡 Promising
Human evidence exists, but studies are small, preliminary or need confirmation.
🟠 Experimental
Evidence is primarily laboratory, animal or early-stage clinical research.
🔴 Insufficient evidence
There is not enough credible clinical evidence to determine whether the therapy works.
This rating system is deliberately different from FDA approval.
A therapy can be 🟡 Promising and still have no FDA approval.
That is exactly the point of this article.
Non-Conventional Does Not Mean “Natural”
Another important distinction:
Not all non-FDA-approved therapies are natural.
- A dietary supplement may be non-conventional.
- A plant compound may be non-conventional.
- A repurposed pharmaceutical drug may be FDA-approved for another disease but not FDA-approved for myeloma.
- An experimental laboratory compound may have never been approved for any human disease.
Therefore, I would not use “natural cancer treatments” as a synonym for non-conventional therapies.
The more accurate phrase is:
Evidence-based, non-conventional multiple myeloma therapies
That allows PeopleBeatingCancer to investigate therapies according to evidence rather than marketing category.
The Biggest Problem With Non-Conventional Cancer Therapies
The problem is not simply that some therapies lack FDA approval.
The bigger problem is that cancer patients are often presented with claims that go far beyond the available evidence.
For example:
Laboratory evidence:
“Compound X kills multiple myeloma cells.”
becomes:
Marketing claim:
“Compound X kills multiple myeloma.”
Those are completely different statements.
A laboratory experiment tells us that something can happen under experimental conditions.
It does not tell us that taking the compound will produce the same result inside a human body.
That requires clinical research.
Why Patients Should Tell Their Oncologist
Non-conventional does not mean harmless.
Dietary supplements and natural products can have biologically active effects and may interact with medications or medical conditions. The FDA specifically advises consumers to discuss supplements with healthcare professionals because some can interact with medicines or pose other risks.
This is particularly important for people with multiple myeloma because patients may have:
- impaired kidney function
- anemia
- thrombocytopenia
- neuropathy
- bone disease
- infection risk
- cardiovascular disease
- liver abnormalities
- anticoagulant use
- upcoming surgery
- stem-cell transplantation
- CAR-T therapy
- bispecific-antibody therapy
A supplement that seems harmless in isolation may not be harmless in a particular patient.
How I Would Evaluate a Non-Conventional Myeloma Therapy
Before taking a new therapy, ask seven questions:
1. Is it FDA-approved for multiple myeloma?
If yes, it isn’t a non-conventional therapy under the definition used in this article.
If no, continue evaluating.
2. What type of evidence exists?
- Laboratory?
- Animal?
- Observational?
- Phase I?
- Phase II?
- Randomized clinical trial?
3. Has the research actually been conducted in multiple myeloma patients?
A study involving breast cancer patients does not automatically establish efficacy in multiple myeloma.
4. What was the endpoint?
Did researchers measure:
- myeloma cell death?
- M-spike?
- complete response?
- MRD?
- progression-free survival?
- overall survival?
- quality of life?
These are not interchangeable outcomes.
5. What dose was studied?
A laboratory study may use concentrations that cannot safely or realistically be achieved in humans.
6. Could it interfere with conventional treatment?
This question is particularly important.
7. Who benefits financially from selling it?
If the person making the claim is also selling the product, skepticism is appropriate.
A Working Evidence Table
| Therapy | FDA-approved for MM? | Human MM evidence? | Current PBC rating |
|---|---|---|---|
| Curcumin | No | Yes — small randomized trial | 🟡 Promising |
| Medicinal mushrooms | No | Yes — small randomized study | 🟡 Promising |
| Resveratrol | No | Very limited | 🟠 Experimental |
| Probiotics/microbiome | No | Emerging | 🟡 Promising/Emerging |
| Dietary fiber | No | Emerging observational/clinical research | 🟡 Promising/Emerging |
| Vitamin D | No as an anti-MM therapy | Some clinical/biological research | 🟠 For direct anti-MM use |
| Omega-3 | No as an anti-MM therapy | Limited direct MM evidence | 🟠 Experimental |
| IV vitamin C | No | Limited/experimental | 🟠 Experimental |
| Berberine | No | Primarily preclinical | 🟠 Experimental |
| EGCG | No | Primarily preclinical/early research | 🟠 Experimental |
| Resveratrol | No | Primarily preclinical | 🟠 Experimental |
| Antineoplastons | No | Insufficient convincing clinical evidence | 🔴 Insufficient |
Important: The ratings above describe the evidence for use against multiple myeloma—not whether the substance has other legitimate medical or nutritional uses.
What Should Patients Take Away From This?
The most important message is neither:
“Natural therapies cure myeloma.”
nor:
“If the FDA hasn’t approved it, don’t bother investigating it.”
The more scientifically honest position is:
Investigate the evidence.
- Some non-conventional therapies will probably fail.
- Some may eventually become FDA-approved drugs.
- Others may prove useful only in combination with conventional treatment.
- Still others may turn out to be useful for symptoms, nutrition, or survivorship rather than for treating the cancer itself.
- And some will remain unsupported despite years of claims.
That is exactly why the evidence matters.
The PeopleBeatingCancer Approach
My approach to non-conventional multiple myeloma therapies is simple:
- Don’t dismiss a therapy because it is unconventional.
- Don’t accept a therapy simply because it is natural.
- Don’t confuse laboratory research with clinical proof.
- Don’t confuse FDA approval with the existence of scientific evidence.
And most importantly:
Don’t let hope replace evidence.
Multiple myeloma patients deserve better than either extreme.
They deserve access to the best available conventional treatment and honest information about therapies that researchers are investigating outside the conventional treatment system.
That is the purpose of this PeopleBeatingCancer resource.
PeopleBeatingCancer’s Non-Conventional Multiple Myeloma Resources
Natural compounds and supplements
- Curcumin vs. Multiple Myeloma
- Multiple Myeloma Therapy – Curcumin
- Multiple Myeloma Therapy – Resveratrol
- Medicinal Mushrooms and Multiple Myeloma
- Probiotics for Myeloma
- Multiple Myeloma Supplements – A How-To Guide
Diet and microbiome
Experimental therapies
Research: What Does the Science Actually Say?
FDA regulation of supplements
FDA — 10 Facts About What FDA Does and Does Not Approve
FDA: 10 Facts About What FDA Does and Does Not Approve
FDA — Questions and Answers About Dietary Supplements
FDA: Questions and Answers About Dietary Supplements
Curcumin
Curcumin as Adjuvant Therapy to Improve Remission in Myeloma Patients: A Pilot Randomized Clinical Trial
PubMed: Curcumin and Multiple Myeloma Randomized Trial
Medicinal mushrooms
Agaricus blazei Murrill-Based Mushroom Extract in Multiple Myeloma During High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
PubMed: Agaricus blazei and Multiple Myeloma
Resveratrol
Resveratrol for Cancer Therapy: Challenges and Future Perspectives
PubMed: Resveratrol Cancer Therapy Review
Microbiome
Minimal Residual Disease Negativity in Multiple Myeloma Is Associated With Intestinal Microbiota Composition
PubMed: Multiple Myeloma and Intestinal Microbiota
Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma
PubMed: Gut Microbiota, SCFAs and Multiple Myeloma Treatment Response
Fiber Intake Associates With Increased Treatment Response in Multiple Myeloma Patients Along With Changes in Gut Microbiome — 2026
PubMed: 2026 Fiber, Microbiome and Multiple Myeloma Study
Non-Conventional Myeloma Therapies Non-Conventional Myeloma Therapies